A detailed history of Vanguard Group Inc transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 12,155,173 shares of SANA stock, worth $65.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,155,173
Previous 9,797,084 24.07%
Holding current value
$65.9 Million
Previous $40 Million 204.09%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$4.2 - $11.27 $9.9 Million - $26.6 Million
2,358,089 Added 24.07%
12,155,173 $122 Million
Q4 2023

Feb 14, 2024

BUY
$2.8 - $4.55 $1.76 Million - $2.86 Million
629,499 Added 6.87%
9,797,084 $40 Million
Q3 2023

Nov 14, 2023

BUY
$3.77 - $6.23 $404,019 - $667,650
107,167 Added 1.18%
9,167,585 $35.5 Million
Q2 2023

Aug 14, 2023

SELL
$3.22 - $7.53 $82,155 - $192,120
-25,514 Reduced 0.28%
9,060,418 $54 Million
Q1 2023

May 15, 2023

BUY
$3.11 - $4.92 $371,013 - $586,941
119,297 Added 1.33%
9,085,932 $29.7 Million
Q4 2022

Feb 10, 2023

BUY
$3.19 - $6.46 $404,345 - $818,830
126,754 Added 1.43%
8,966,635 $35.4 Million
Q3 2022

Nov 14, 2022

BUY
$5.58 - $9.04 $4.39 Million - $7.12 Million
787,470 Added 9.78%
8,839,881 $53 Million
Q2 2022

Aug 12, 2022

BUY
$4.12 - $9.35 $1.58 Million - $3.58 Million
382,729 Added 4.99%
8,052,411 $51.8 Million
Q1 2022

May 13, 2022

SELL
$5.24 - $15.58 $201,577 - $599,347
-38,469 Reduced 0.5%
7,669,682 $63.4 Million
Q4 2021

Feb 14, 2022

BUY
$15.18 - $23.15 $1.82 Million - $2.77 Million
119,607 Added 1.58%
7,708,151 $119 Million
Q3 2021

Nov 12, 2021

BUY
$16.29 - $25.88 $83.5 Million - $133 Million
5,127,363 Added 208.33%
7,588,544 $171 Million
Q2 2021

Aug 13, 2021

BUY
$16.65 - $32.14 $41 Million - $79.1 Million
2,461,181 New
2,461,181 $48.4 Million

Others Institutions Holding SANA

About Sana Biotechnology, Inc.


  • Ticker SANA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 190,232,000
  • Market Cap $1.03B
  • Description
  • Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
More about SANA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.